Mauna Kea Technologies Announces That 50 Scientific Articles Published on Cellvizio(R) in 2011 Underscore the Value of Endomicroscopy
Data Show That Adding Cellular-Level Imaging to Standard Endoscopy Procedures Opens the Possibility of Improved Cancer Detection and Treatment Algorithms
(firmenpresse) - PARIS -- (Marketwire) -- 01/04/12 -- Mauna Kea Technologies (EURONEXT PARIS: MKEA), the leader in the endomicroscopy market, today announced that 50 peer-reviewed scientific articles published on Cellvizio® during 2011 underscore the value of adding cellular-level imaging to endoscopy procedures. The publications, which include 35 on clinical applications, show the strong interest towards endomicroscopic imaging with Cellvizio.
These publications underscore the enormous progress of the medical community in the understanding of endomicroscopy applications for better diagnosis and more appropriate individualized patient care -- in gastroenterology and pulmonology, as well as newer investigational applications such as urology.
"Thanks to this small, flexible microscope, we can reach places that were previously difficult to access," explained Vani Konda, MD, a gastroenterologist at the University of Chicago Medical Center who has used Cellvizio since 2008. "We now benefit from a large body of clinical research work performed in the gastrointestinal field with Cellvizio. It helps us understand how endomicroscopy with probe-based techniques can improve our real-time assessment of regions of interest and pathologies during the endoscopy examination. With this advanced imaging technology, we are able to provide our patients with more accurate diagnoses and faster, more appropriate treatments."
The complete listing of published clinical studies with Cellvizio® is available on Mauna Kea Technologies' web site:
Mauna Kea Technologies is a global medical device company and a leader in endomicroscopic innovation. The company designs, develops and markets innovative tools to visualize and help detect abnormalities in the gastrointestinal and pulmonary tracts. Its flagship product (Cellvizio®, a probe-based confocal laser endomicroscopy (pCLE) system) provides physicians and researchers with high-resolution cellular views of tissue inside the body. Large, international, multicenter clinical trials have demonstrated Cellvizio®'s ability to help physicians more accurately detect early forms of disease and make treatment decisions immediately. Designed to improve patient outcomes and reduce hospital costs, Cellvizio can be used with almost any endoscope. Cellvizio® has 510(k) clearance from the U.S. Food and Drug Administration and the European CE-Mark for use in the gastrointestinal and pulmonary tracts.
For more information on Mauna Kea Technologies, visit
This press release and the information contained herein do not constitute an offer to sell or subscribe to, or a solicitation of an offer to buy or subscribe to, shares in Mauna Kea Technologies ("the Company") in any country. This press release contains forward-looking statements that relate to the Company's objectives. Such forward-looking statements are based solely on the current expectations and assumptions of the Company's management and involve risk and uncertainties. Potential risks and uncertainties include, without limitation, whether the Company will be successful in implementing its strategies, whether there will be continued growth in the relevant market and demand for the Company's products, new products or technological developments introduced by competitors, and risks associated with managing growth. Unfavorable developments in connection with these and other risks and uncertainties described, in particular, in the Company's prospectus prepared in connection with its IPO and on which the French Autorité des marches financiers ("AMF") granted its visa number 11-236 on June 230, 2011, could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.
Lazar Partners Ltd.
Tel: +1 917 497 2867
Caroline Carmagnol
Tel: + 33 1 42 68 86 43 / + 33 6 64 18 99 59
Anne-Sophie Cosqueric
Tel: + 33 1 42 68 86 41
Alexander Bryson
Marketing Communications and Brand Manager
Tel: +33 (0) 1 70 08 09 92
NewInvestor Relations and Financial Communication
Pierre Laurent / Florent Alba
Tel: +33 1 44 71 94 94
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 04.01.2012 - 10:45 Uhr
Sprache: Deutsch
News-ID 1069939
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
PARIS
Phone:
Kategorie:
Medical Devices
Anmerkungen:
Diese Pressemitteilung wurde bisher 143 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Mauna Kea Technologies Announces That 50 Scientific Articles Published on Cellvizio(R) in 2011 Underscore the Value of Endomicroscopy
"
steht unter der journalistisch-redaktionellen Verantwortung von
Mauna Kea Technologies (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
